169 related articles for article (PubMed ID: 17894531)
1. In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers.
Zhang Y; Gilbertson K; Finlay WH
J Aerosol Med; 2007; 20(3):227-35. PubMed ID: 17894531
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Bio-relevant Mouth-Throat Models for Characterization of Metered Dose Inhalers.
Kaviratna A; Tian G; Liu X; Delvadia R; Lee S; Guo C
AAPS PharmSciTech; 2019 Feb; 20(3):130. PubMed ID: 30815748
[TBL] [Abstract][Full Text] [Related]
3. In vitro investigation of the effect of ambient humidity on regional delivered dose with solution and suspension MDIs.
Shemirani FM; Hoe S; Lewis D; Church T; Vehring R; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2013 Aug; 26(4):215-22. PubMed ID: 23094687
[TBL] [Abstract][Full Text] [Related]
4. Comparison of in vitro deposition of pharmaceutical aerosols in an idealized child throat with in vivo deposition in the upper respiratory tract of children.
Ruzycki CA; Golshahi L; Vehring R; Finlay WH
Pharm Res; 2014 Jun; 31(6):1525-35. PubMed ID: 24395403
[TBL] [Abstract][Full Text] [Related]
5.
Wei X; Hindle M; Kaviratna A; Huynh BK; Delvadia RR; Sandell D; Byron PR
J Aerosol Med Pulm Drug Deliv; 2018 Dec; 31(6):358-371. PubMed ID: 29878859
[No Abstract] [Full Text] [Related]
6. In vitro effect of a holding chamber on the mouth-throat deposition of QVAR (hydrofluoroalkane-beclomethasone dipropionate).
Rahmatalla MF; Zuberbuhler PC; Lange CF; Finlay WH
J Aerosol Med; 2002; 15(4):379-85. PubMed ID: 12581504
[TBL] [Abstract][Full Text] [Related]
7. A dry powder inhaler with reduced mouth-throat deposition.
Wang ZL; Grgic B; Finlay WH
J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
[TBL] [Abstract][Full Text] [Related]
8. An Exploration of Factors Affecting
Ruzycki CA; Martin AR; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):405-417. PubMed ID: 31418632
[No Abstract] [Full Text] [Related]
9. Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach.
Worth Longest P; Hindle M
J Aerosol Med Pulm Drug Deliv; 2009 Jun; 22(2):99-112. PubMed ID: 18956950
[TBL] [Abstract][Full Text] [Related]
10. In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices.
DeHaan WH; Finlay WH
J Aerosol Med; 2001; 14(3):361-7. PubMed ID: 11693848
[TBL] [Abstract][Full Text] [Related]
11. Studies of the human oropharyngeal airspaces using magnetic resonance imaging IV--the oropharyngeal retention effect for four inhalation delivery systems.
Burnell PK; Asking L; Borgström L; Nichols SC; Olsson B; Prime D; Shrubb I
J Aerosol Med; 2007; 20(3):269-81. PubMed ID: 17894534
[TBL] [Abstract][Full Text] [Related]
12. Deposition of Particles in Human Mouth-Throat Replicas and a USP Induction Port.
Cheng YS; Zhou Y; Su WC
J Aerosol Med Pulm Drug Deliv; 2015 Jun; 28(3):147-55. PubMed ID: 25137223
[TBL] [Abstract][Full Text] [Related]
13. In vitro evaluation of nonconventional accessory devices for pressurized metered-dose inhalers.
Sheth P; Bertsch MD; Knapp CL; Myrdal PB
Ann Allergy Asthma Immunol; 2014 Jul; 113(1):55-62. PubMed ID: 24814758
[TBL] [Abstract][Full Text] [Related]
14. In Vitro and In Silico Investigations on Drug Delivery in the Mouth-Throat Models with Handihaler®.
Huang F; Zhou X; Dai W; Yu J; Zhou Z; Tong Z; Yu A
Pharm Res; 2022 Nov; 39(11):3005-3019. PubMed ID: 36071350
[TBL] [Abstract][Full Text] [Related]
15. Effect of facial material softness and applied force on face mask dead volume, face mask seal, and inhaled corticosteroid delivery through an idealized infant replica.
Carrigy NB; O'Reilly C; Schmitt J; Noga M; Finlay WH
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):290-8. PubMed ID: 24219815
[TBL] [Abstract][Full Text] [Related]
16. Impact of droplet evaporation rate on resulting in vitro performance parameters of pressurized metered dose inhalers.
Sheth P; Grimes MR; Stein SW; Myrdal PB
Int J Pharm; 2017 Aug; 528(1-2):360-371. PubMed ID: 28599855
[TBL] [Abstract][Full Text] [Related]
17. In Vitro-In Vivo Correlations Observed With Indacaterol-Based Formulations Delivered with the Breezhaler®.
Weers JG; Clark AR; Rao N; Ung K; Haynes A; Khindri SK; Perry SA; Machineni S; Colthorpe P
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):268-80. PubMed ID: 25517988
[TBL] [Abstract][Full Text] [Related]
18. Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: a scoping study with the "Alberta" idealized throat (AIT) inlet.
Mitchell J; Copley M; Sizer Y; Russell T; Solomon D
J Aerosol Med Pulm Drug Deliv; 2012 Aug; 25(4):188-97. PubMed ID: 22857270
[TBL] [Abstract][Full Text] [Related]
19. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
Pitcairn G; Reader S; Pavia D; Newman S
J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
[TBL] [Abstract][Full Text] [Related]
20. De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products.
Leung SS; Tang P; Zhou QT; Tong Z; Leung C; Decharaksa J; Yang R; Chan HK
AAPS J; 2015 Nov; 17(6):1407-16. PubMed ID: 26201967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
